FDA Expands Casgevy Approval to Children as Young as 2
WASHINGTON, D.C. — The U.S. Food and Drug Administration has expanded approval of the gene therapy Casgevy to include children as young as 2 with sickle cell disease or transfusion-dependent …
FDA Expands Casgevy Approval to Children as Young as 2 Read More